Compare TSBK & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | STTK |
|---|---|---|
| Founded | 1915 | 2016 |
| Country | United States | United States |
| Employees | 280 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.8M | 275.9M |
| IPO Year | 1997 | 2020 |
| Metric | TSBK | STTK |
|---|---|---|
| Price | $37.85 | $6.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 16.6K | ★ 581.3K |
| Earning Date | 04-21-2026 | 03-05-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | 21.93 | ★ 53.02 |
| EPS | ★ 1.04 | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.24 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.51 | $0.69 |
| 52 Week High | $40.41 | $6.27 |
| Indicator | TSBK | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 43.92 | 71.72 |
| Support Level | $37.56 | $1.85 |
| Resistance Level | $38.18 | N/A |
| Average True Range (ATR) | 0.81 | 0.42 |
| MACD | -0.14 | 0.09 |
| Stochastic Oscillator | 20.88 | 89.41 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.